Oral Polio Vaccine

Introduction

Oral Polio Vaccine (OPV) is a live attenuated vaccine used to immunize individuals, primarily children, against poliomyelitis, a viral disease that can cause paralysis and even death. It was introduced in the 1960s and played a crucial role in the near-eradication of polio worldwide. OPV is administered orally, which makes it easy to distribute in mass vaccination campaigns, especially in developing countries.

Uses

OPV is used for:

• Prevention of poliomyelitis (polio) caused by poliovirus types 1, 2, and 3
• Mass immunization campaigns aimed at eradicating polio globally
• Protection of individuals in areas with ongoing polio transmission

Mechanism of Action

The live attenuated poliovirus in OPV replicates in the intestine, triggering an immune response. This response involves the production of antibodies that neutralize poliovirus, preventing infection. OPV also induces mucosal immunity in the intestines, reducing viral shedding and transmission. This community-level immunity is a major factor in polio eradication campaigns.

How Long Does It Take to Work?

After administration, OPV begins to work within days by inducing an immune response in the intestines. Full immunity usually develops after 2-3 doses, although a single dose provides partial protection.

Absorption

OPV is administered orally and acts locally in the intestines. The attenuated virus replicates in the gut, where it induces both humoral and mucosal immunity.

Route of Elimination

The vaccine virus is excreted in the stool of vaccinated individuals for several weeks, which can indirectly help immunize others through community spread of the attenuated virus.

Dosage

The World Health Organization (WHO) recommends a primary series of 3 doses of OPV, starting at 6 weeks of age. Additional booster doses may be given at intervals depending on local polio eradication strategies.

Administration

OPV is administered orally. It is given as drops, usually during mass vaccination campaigns or routine immunization schedules for children. No needles are involved, making it easier to administer in large-scale public health settings.

Side Effects

Common side effects of OPV are mild and may include:

• Mild fever
• Diarrhea
• Fatigue

Toxicity

OPV is generally safe, with no toxic effects. However, the rare occurrence of VAPP is a recognized risk, occurring in approximately 1 in 2.7 million doses. This risk is why many countries have transitioned to the inactivated polio vaccine (IPV) in their routine immunization schedules.

Precautions

Precautions should be taken when administering OPV to:

• Individuals with weakened immune systems (e.g., those with HIV/AIDS or undergoing immunosuppressive therapy)
• Individuals in close contact with immunocompromised persons, due to the potential risk of viral transmission

Interaction

There are no significant drug interactions with OPV. However, the immune response may be blunted in individuals on immunosuppressive medications or those with immune deficiencies.

Disease Interaction

OPV should be used with caution in individuals with primary immunodeficiency disorders or other conditions that weaken the immune system, as they are at higher risk for vaccine-associated paralytic poliomyelitis.

Drug Interaction

No major drug interactions have been reported with OPV. However, individuals on immunosuppressive therapy may have a reduced immune response to the vaccine.

Food Interactions

There are no significant food interactions with OPV. The vaccine can be administered with or without food.

Pregnancy Use

OPV is not typically recommended for pregnant women, as there is a theoretical risk of fetal harm, although no direct evidence exists. In general, pregnant women are advised to receive the inactivated polio vaccine (IPV) instead of OPV.

Lactation Use

There is no evidence to suggest that OPV poses a risk to breastfeeding infants. It can be safely administered to breastfeeding mothers.

Acute Overdose

There are no reports of overdose with OPV. If an extra dose is administered, no specific treatment is required, and the risk of adverse effects remains low.

Contraindication

OPV is contraindicated in:

• Individuals with known hypersensitivity to any component of the vaccine
• Individuals with primary immunodeficiency or immunosuppressive conditions

Use Direction

OPV is administered as oral drops. The exact dosage schedule may vary by country, but typically, 2-3 doses are given in infancy, with additional doses during mass immunization campaigns. Care must be taken to ensure the vaccine is not contaminated during administration.

Storage Conditions

OPV should be stored at temperatures between -20°C and 8°C to maintain its efficacy. It is important to avoid exposure to heat and light, as these can degrade the live virus.

Volume of Distribution

After oral administration, the attenuated poliovirus remains localized in the intestines, where it replicates and induces immunity. There is no systemic distribution as with injected vaccines.

Half Life

The attenuated poliovirus in OPV replicates in the intestines and is shed in the stool for several weeks. The exact half-life is not applicable, but viral shedding may persist for up to 6 weeks.

Clearance

OPV is cleared through fecal excretion, as the attenuated virus is shed in the stool. This viral shedding is part of its effectiveness in inducing community immunity.